There is a lot going on in the Rheumatoid Arthritis (RA) market at the moment with news last week from Pfizer that tofacitinib had met its study endpoints. A number of new products in the pipeline will have an impact on this Pharma market.
RA is an autoimmune disease that causes chronic inflammation of the joints. It’s a particularly painful and crippling disease for those affected. Monoclonal antibodies such as adalimumab (Humira), infliximab (Remicade) and natalizumab (Tysabri) have been shown to be effective at relieving RA symptoms through their inhibition of Tumor Necrosis Factor-α (TNF-α).
However, as Sally Church in a post on Pharma Strategy Blog notes, one of the challenges of these biologics is that about 28% of RA patients develop antidrug antibodies, resulting in resistance and lower treatment response.
Sally reviews recent research published in the Journal of the American Medical Association (JAMA) by Geertje Bartelds and colleagues that looked at the correlation between outcomes and development of antibodies to adalimumab (Humira).
The findings from this research suggest that we may be able to optimize RA treatment based on monitoring of antidrug antibodies. You can read more about this research on Pharma Strategy Blog.